Floatz logo

Tabelecleucel

Post-Transplant Lymphoproliferative Disease

Pierre Fabre MedicamentCell therapyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Post-Transplant Lymphoproliferative Disease cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Jennifer Amengual
Phase 2BBB
Cyclophosphamide
Washington University School of Medicine
Phase 2BBB
cc-5013
Northwestern University
Phase 2BB
Fludarabine
City of Hope Medical Center
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 47 →

Same molecule, other indications

Tabelecleucel is also rated in:

disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
BB
Indicative ·
66 / 100
View asset →
Solid Organ Transplant ComplicationsDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →